PD-1/PD-L1 inhibitors have been approved for patients with progressive urothelial carcinoma during or after chemotherapy based on phase II/III studies; therefore, the opportunities for the administration of anti-PD-1/PD-L1 antibodies have been increasing in patients with UTUC who received RT [5]. Here, CD274 is linked to urothelial carcinoma.